Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) have received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $12.6667.

Several equities analysts recently issued reports on the company. Craig Hallum began coverage on Alterity Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $12.00 price target on the stock. JonesTrading initiated coverage on Alterity Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $16.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a report on Friday, July 17th. LADENBURG THALM/SH SH began coverage on Alterity Therapeutics in a research note on Tuesday, June 16th. They set a “buy” rating and a $10.00 price target for the company. Finally, Zacks Research raised Alterity Therapeutics to a “hold” rating in a report on Wednesday, June 17th.

Institutional Trading of Alterity Therapeutics

An institutional investor recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC bought a new stake in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.25% of Alterity Therapeutics as of its most recent SEC filing. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Stock Up 3.0%

Shares of NASDAQ:ATHE opened at $4.58 on Tuesday. Alterity Therapeutics has a one year low of $2.66 and a one year high of $5.89. The company has a 50-day simple moving average of $4.76 and a 200-day simple moving average of $4.13.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.